215 related articles for article (PubMed ID: 30301385)
1. Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase.
Konishi K; Minematsu T; Nagasaka Y; Tabata K
Xenobiotica; 2019 Aug; 49(8):912-921. PubMed ID: 30301385
[TBL] [Abstract][Full Text] [Related]
2. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Konishi K; Minematsu T; Nagasaka Y; Tabata K
Biopharm Drug Dispos; 2019 May; 40(5-6):176-187. PubMed ID: 30985942
[TBL] [Abstract][Full Text] [Related]
3. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
5. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.
Klose M; Cristofoletti R; Silva CM; Mangal N; Turgeon J; Michaud V; Lesko LJ; Schmidt S
Eur J Pharm Sci; 2024 Mar; 194():106689. PubMed ID: 38171419
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
7. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
[TBL] [Abstract][Full Text] [Related]
8. Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions.
Kilford P; Khoshaein N; Southall R; Gardner I
Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):699-710. PubMed ID: 35840839
[TBL] [Abstract][Full Text] [Related]
9. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist.
Takusagawa S; Yajima K; Miyashita A; Uehara S; Iwatsubo T; Usui T
Xenobiotica; 2012 Oct; 42(10):957-67. PubMed ID: 22509825
[TBL] [Abstract][Full Text] [Related]
10. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo.
Johnson TN; Howgate EM; de Wildt SN; Turner MA; Rowland Yeo K
Drug Metab Dispos; 2023 Aug; 51(8):1035-1045. PubMed ID: 37169511
[TBL] [Abstract][Full Text] [Related]
11. Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase 2B7: evidence for protein-protein association and possible involvement of CYP3A4 J-helix in the interaction.
Takeda S; Ishii Y; Iwanaga M; Nurrochmad A; Ito Y; Mackenzie PI; Nagata K; Yamazoe Y; Oguri K; Yamada H
Mol Pharmacol; 2009 Apr; 75(4):956-64. PubMed ID: 19158361
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Modeling to Predict the Impact of Liver Cirrhosis on Glucuronidation via UGT1A4 and UGT2B7/2B4-A Case Study with Midazolam.
Ozbey AC; Keemink J; Wagner B; Pugliano A; Krähenbühl S; Annaert P; Fowler S; Parrott N; Umehara K
Drug Metab Dispos; 2024 Jun; 52(7):614-625. PubMed ID: 38653501
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid.
Callegari E; Lin J; Tse S; Goosen TC; Sahasrabudhe V
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):127-136. PubMed ID: 33314761
[TBL] [Abstract][Full Text] [Related]
14. Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.
Stader F; Battegay M; Marzolini C
Clin Pharmacol Ther; 2021 Nov; 110(5):1231-1239. PubMed ID: 33626178
[TBL] [Abstract][Full Text] [Related]
15. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
17. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324
[TBL] [Abstract][Full Text] [Related]
18. Suppression of Cytochrome P450 3A4 Function by UDP-Glucuronosyltransferase 2B7 through a Protein-Protein Interaction: Cooperative Roles of the Cytosolic Carboxyl-Terminal Domain and the Luminal Anchoring Region.
Miyauchi Y; Nagata K; Yamazoe Y; Mackenzie PI; Yamada H; Ishii Y
Mol Pharmacol; 2015 Oct; 88(4):800-12. PubMed ID: 26243732
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.
Asaumi R; Toshimoto K; Tobe Y; Hashizume K; Nunoya KI; Imawaka H; Lee W; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):186-196. PubMed ID: 29368402
[TBL] [Abstract][Full Text] [Related]
20. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
